Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 天美传媒 Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Pathological analysis and evaluation of a liver biopsy is an important step in the diagnosis of single or multiple mass lesions in
the liver. Accurate diagnosis is paramount in guiding appropriate treatment. This study conducted a search for liver biopsies
for the past 6 years with the diagnostic search codes of neoplasm, metastases, metastatic, adenocarcinoma, neuroendocrine
carcinoma, sarcoma, and lymphoma. The aim was to review their pathological workup with a view to developing cost-efficient
immunohistochemical diagnostic algorithms. A total of 375 consecutive neoplastic liver biopsies were retrieved and subjected
to pathological review. As expected the majority up to 95% of the neoplastic lesions were metastatic lesions. A few biopsies
up to 1% represented primary hepatocellular /cholangiocarcinoma, haemangioma, and cirrhosis. The commonest metastases
[upto 61%] to the liver were colorectal in origin being Hepar-ve, CDX2+ve, and CK20+/CK7-ve. Other lesions included
metastases from pancreas [12%], lung [8%] upper gastrointestinal [8%], neuroendocrine lesions [8%], ovarian [1%] and
kidney/urothelial [2%]. Uncommon metastases encountered included hepatic metastatic meningioma, endometrial stromal
sarcoma, and osteosarcoma. Immunohistochemical stains were the most useful test in identifying the primary site of the
tumor. Though diagnostic algorithms were developed especially in the case of the unknown primary, some biopsies received
a differential diagnosis of more than one organ as the primary site for clinicopathological correlation. As liver metastases
are usually easily accessible for core needle biopsy; accurate identification/specifics of the liver metastases are paramount for
individualized precision medicine of treatment that may thus direct surgical resection, radiofrequency ablation/embolization
or medical adjuvant therapy as indicated.
Biography
Rani Kanthan is a consultant Anatomical pathologist in the Deptartment of Pathology and Laboratory Medicine at the University of Saskatchewan with a focused interest in surgical oncology including breast and gastrointestinal tract. She has published 122 peer-reviewed manuscripts that are indexed in PubMed/Google scholar and serves as an editorial board member in various journals. She is an active medical educator and continues to participate and present at various national and international meetings with more than 132 conference abstract presentations to her credit.